Licofelone abolishes survival of carcinogenic fibroblasts by inducing apoptosis

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Dual inhibitors of cyclooxygenase (COX) and lipoxygenase (LOX) pathways are crucial for preventing cancer development and inducing apoptosis.
• Licofelone is a promising compound that inhibits both COX and LOX pathways.
• The study investigates the effects of licofelone on H-ras transformed rat embryonic fibroblast (5RP7) cells.

Purpose of the Study:

• To determine if licofelone affects the survival of H-ras transformed 5RP7 cells in vitro.
• To assess the apoptosis-inducing potential of licofelone in these cells.
• To compare licofelone's effects with positive controls 5-fluorouracil (5-FU) and colchicine.

Main Methods:

• Cell viability was assessed using the MTT assay.
• Apoptosis was measured by flow cytometry.
• Caspase enzyme activity was quantified using real-time reverse transcription PCR.

Main Results:

• Licofelone, 5-FU, and colchicine exhibited dose-dependent cytotoxicity, reducing cell numbers by up to 92%, 78%, and 72%, respectively.
• Licofelone induced apoptosis and necrosis in a dose- and time-dependent manner.
• All tested drugs increased caspase-3 enzyme levels up to 5-fold at 250 µM.
• Licofelone demonstrated a superior capacity to induce total apoptosis (early plus late) at approximately 96% after 48 hours compared to colchicine.

Conclusions:

• Licofelone exhibits potent dose- and time-dependent anticancer and apoptotic properties against carcinogenic fibroblasts.
• The findings suggest licofelone's potential as a therapeutic agent for cancer treatment.
• Licofelone's dual inhibition of COX and LOX pathways contributes to its observed anti-cancer effects.